Dual role of interleukin-2 in tumor-infiltrating lymphocyte therapy

Abstract

Tumor-infiltrating lymphocyte (TIL) therapy has become a promising immunotherapy for the treatment of solid tumors and has shown substantial therapeutic potential in recent years, offering new options for patients with cancer. Despite its encouraging clinical outcomes, TIL therapy continues to face several research challenges and unresolved issues. Interleukin-2 (IL-2) is a key cytokine in TIL therapy and plays a critical role by promoting TIL proliferation and enhancing their anti-tumor activity. However, the administration of IL-2 may also lead to a range of adverse effects. This study reviews recent clinical research progress in TIL therapy, with particular emphasis on the dual role of IL-2 in this treatment approach. By examining current clinical trial data and recent research findings, this study evaluates both the beneficial effects and potential risks of IL-2 in TIL therapy and aims to provide guidance for future research and clinical practice.

Keywords

Tumor-infiltrating lymphocyte / Solid tumor / Interleukin-2 / Immunotherapy / Clinical research

References

[1] Monberg TJ, et al. . TIL therapy: facts and hopes. Clin Cancer Res, 2023, 29(17): 3275-3283

[2] Amaria R, et al. . Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer, 2024, 12(2): e006822

[3] Stevanovic S, et al. . Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol, 2015, 33(14): 1543-1550

[4] Stevanovic S, et al. . A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res, 2019, 25(5): 1486-1493

[5] Zacharakis N, et al. . Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol, 2022, 40(16): 1741-1754

[6] Schoenfeld AJ, et al. . Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov, 2024, 14(8): 1389-1402

[7] Creelan BC, et al. . Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med, 2021, 27(8): 1410-1418

[8] Mullard A. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. Nat Rev Drug Discov, 2024, 23(4): 238

[9] Trentin L, et al. . Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. Br J Cancer, 1994, 69(6): 1046-1051

[10] Malek TR. The biology of interleukin-2. Annu Rev Immunol, 2008, 26: 453-479

[11] Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf, 2017, 16(12): 1347-1357

[12] Amaria RN, et al. . Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation. Cytotherapy, 2024, 27(7): 864-73

[13] Granhoj JS, et al. . Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. Expert Opin Biol Ther, 2022, 22(5): 627-641

[14] Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015, 348(6230): 62-68

[15] Borch TH, et al. . Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer, 2020, 8(2): e000668

[16] Martin-Lluesma S, et al. . Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Ann Oncol, 2024, 35(10): 860-872

[17] Besser MJ, et al. . Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. Mol Carcinog, 2020, 59(7): 736-744

[18] Seitter SJ, et al. . Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res, 2021, 27(19): 5289-5298

[19] Sarnaik AA, et al. . Lifileucel, a tumor-infiltrating lymphocyte therapy. Metastatic Melanoma J Clin Oncol, 2021, 39(24): 2656-2666

[20] Rohaan MW, et al. . Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med, 2022, 387(23): 2113-2125

[21] Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755.

[22] Orcurto A, Chiffelle J, Ghisoni E, et al. In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study. J Clin Oncol. 021;39(15_suppl):2533.

[23] Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol. 2019;37(15_suppl):2538.

[24] Tran E, et al. . T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med, 2016, 375(23): 2255-2262

[25] Tran E, et al. . Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science, 2014, 344(6184): 641-645

[26] Dudley ME, et al. . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005, 23(10): 2346-2357

[27] Guo J, et al. . IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer. BMC Med, 2024, 22(1): 207

[28] Amaria RN, et al. . OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. J Clin Oncol, 2024, 42(16_suppl): 9515-9515

[29] Guo J, et al. . A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer. J Clin Oncol, 2024, 42(16_suppl): 5552-5552

[30] Zhang L, et al. . Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res, 2015, 21(10): 2278-2288

[31] Wolf B, et al. . Safety and tolerability of adoptive cell therapy in cancer. Drug Saf, 2019, 42(2): 315-334

[32] Dafni U, et al. . Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol, 2019, 30(12): 1902-1913

[33] Yang JC. Toxicities associated with adoptive T-cell transfer for cancer. Cancer J, 2015, 21(6): 506-509

[34] U.S. Food and Drug Administration. AMTAGVI (lifileucel) suspension for intravenous infusion Initial U.S. Approval: 2024. [2025-04-21]. https://www.fda.gov/media/176417/download.

[35] Fradley MG, et al. . Cardiovascular Toxicity and Mortality Associated With Adoptive Cell Therapy and Tumor-infiltrating Lymphocytes for Advanced Stage Melanoma. J Immunother, 2021, 44(2): 86-89

[36] Dutcher JP, et al. . High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J Immunother Cancer, 2014, 2(1): 26

[37] Karakus U, et al. . Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species. Sci Transl Med, 2020, 12(574): eabb9283

[38] Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol, 2003, 74(6): 961-965

[39] Migone TS, et al. . The deubiquitinating enzyme DUB-2 prolongs cytokine-induced signal transducers and activators of transcription activation and suppresses apoptosis following cytokine withdrawal. Blood, 2001, 98(6): 1935-1941

[40] Johnston JA, et al. . Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci U S A, 1995, 92(19): 8705-8709

[41] Kalia V, Sarkar S. Regulation of effector and memory CD8 T cell differentiation by IL-2-a balancing act. Front Immunol, 2018, 9: 2987

[42] Lotze MT, et al. . Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res, 1981, 41(11 Pt 1): 4420-4425

[43] Grimm EA, et al. . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med, 1982, 155(6): 1823-1841

[44] Inozume T, et al. . Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother, 2010, 33(9): 956-964

[45] Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 1986, 233(4770): 1318-1321

[46] Rosenberg SA, et al. . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med, 1988, 319(25): 1676-1680

[47] Goff SL, et al. . Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol, 2016, 34(20): 2389-2397

[48] Rosenberg SA, et al. . Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res, 2011, 17(13): 4550-4557

[49] Creelan BC, et al. . 1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results. J Immunother Cancer, 2024, 12(Suppl 3): A1718

[50] Jazaeri AA, et al. . Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol, 2019, 37(15_suppl): 2538-2538

[51] Son J, et al. . Adoptive cell therapy in gynecologic cancers: a systematic review and meta-analysis. Gynecol Oncol, 2022, 165(3): 664-670

[52] Liang YJ, et al. . A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients. Eur J Cancer, 2023, 191: 112965

[53] U.S. Food and Drug Administration. PROLEUKIN® (aldesleukin) for injection, for intravenous infusion. [2025-04-21]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf.

[54] Schwartz RN, Stover L, Dutcher JP. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park), 2002, 16(11 Suppl 13): 11-20

[55] Sharma M, et al. . Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun, 2020, 11(1): 661

[56] Stenehjem DD, et al. . Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother, 2016, 65(8): 941-949

[57] Poust JC, Woolery JE, Green MR. Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs, 2013, 24(1): 1-13

[58] Liu Y, et al. . IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol, 2021, 22(3): 358-369

[59] Sun Q, Dong C. Regulators of CD8(+) T cell exhaustion. Nat Rev Immunol, 2026, 26(2): 129-151

[60] Zhou P, et al. . Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature, 2023, 624(7990): 154-163

[61] U.S. Food and Drug Administration. PROLEUKIN (aldesleukin) for injection, for intravenous use Initial U.S. Approval: 1992. [2025-04-21]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103293s51,54lbl.pdf.

[62] Iovance Biotherapeutics. Iovance Biotherapeutics announces clinical program update for LN-145 in non-small cell lung cancer. [2025-04-21]. https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-announces-clinical-program-update-ln-145.

[63] Wang T, et al. . Interleukin (IL)-2 is a key regulator of T helper 1 and T helper 2 cytokine expression in fish: functional characterization of two divergent IL2 paralogs in salmonids. Front Immunol, 2018, 9: 1683

[64] Hinrichs CS, et al. . IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood, 2008, 111(11): 5326-5333

[65] Guo J, et al. . Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen. J Immunother Cancer, 2022, 10(2): e003887

[66] Schluns KS, et al. . Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol, 2000, 1(5): 426-432

[67] Zhang Y, et al. . 403 Tumor-infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro. J Immunother Cancer, 2023, 11(Suppl 1): A452

[68] Gattinoni L, et al. . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med, 2005, 202(7): 907-912

[69] Liau NPD, et al. . The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun, 2018, 9(1): 1558

[70] Wong K, et al. . 204 KSQ-004: unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors. J Immunother Cancer, 2021, 9(Suppl 2): A215

RIGHTS & PERMISSIONS

The Author(s)